Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Pulmonology · Asthma

Biologics for Severe Environmental Asthma

At a Glance

Biologics can help people with severe environmental or occupational asthma that remains uncontrolled despite correct inhaler use and trigger control. Doctors match treatment to biomarkers such as IgE, eosinophils, or FeNO and monitor response and safety.

When environmental or occupational asthma remains uncontrolled despite high-dose inhalers and addressing workplace triggers, your doctor may classify your condition as severe asthma [1]. For these patients, advanced specialist treatments called biologics can target the specific immune pathways causing the inflammation [2].

It is important to note that a biologic does not make ongoing exposure to a sensitizing workplace chemical safe.

“Severe” vs. “Difficult-to-Treat” Asthma

Before starting a biologic, doctors distinguish between two categories [1]:

  • Difficult-to-Treat Asthma: Asthma that is uncontrolled due to factors like poor inhaler technique, missed medication doses, smoking, or ongoing exposure to workplace triggers [3][4]. Fixing these issues often improves control without needing more intense drugs [5].
  • Severe Asthma: A subset of asthma that stays uncontrolled even when you use your inhalers perfectly, address comorbidities, and control environmental triggers [1][6].

Research indicates that many patients initially thought to have severe asthma actually have “difficult-to-treat” asthma that improves once inhaler technique and adherence are addressed [3].

How Doctors Choose a Biologic

Biologics are selected through a specialist assessment. Your doctor uses biomarkers—measurable signs in your blood or breath—along with your exacerbation history, comorbidities, and weight to determine eligibility [2][7]. Eligibility thresholds vary by product and country.

Target: Allergic Pathways (Anti-IgE)

If your asthma is driven by allergies, a biologic like omalizumab targets IgE, the antibody responsible for allergic reactions [7]. This may be an option if you have an appropriate allergic phenotype and IgE level [8].

Target: Eosinophils (Anti-IL5/5R)

Many people with severe asthma have elevated eosinophils (a type of white blood cell) [2]. Biologics like mepolizumab, reslizumab, and benralizumab target IL-5, the signal that regulates these cells [9].

Target: Dual Pathways (Anti-IL4/13)

Dupilumab targets two signals (IL-4 and IL-13) involved in Type 2 inflammation [2]. It is often used for patients with high FeNO (a gas in your breath that marks inflammation) or those who are dependent on oral steroid pills [9][10].

Target: Upstream Signals (Anti-TSLP)

Tezepelumab targets TSLP, a signal higher up in the immune cascade [11]. Because it works near the “start” of the inflammatory process, it has shown benefit across a broad range of biomarker profiles [12].

Safety and Potential Harms

While biologics are generally well-tolerated, they have specific risks that require monitoring [13].

Eosinophilia and EGPA

A known side effect of dupilumab is a transient rise in blood eosinophils [14]. For many, this resolves on its own [15]. However, patients should be monitored for symptomatic complications, including a rare condition called Eosinophilic Granulomatosis with Polyangiitis (EGPA)—a serious blood vessel inflammation [14][16]. EGPA may also be unmasked when oral steroids are reduced. You should promptly report symptoms like numbness, tingling, worsening respiratory symptoms, or a new rash to your clinician [17].

Other Side Effects

  • Injection-Site Reactions: Redness or swelling where the shot was given is common [18].
  • Anaphylaxis: All biologics carry a small risk of a severe allergic reaction, so administration and observation protocols (which may involve the first doses in a clinic) follow local guidelines [13].

Evaluating Your Response

A biologic is typically trialed for a clinically appropriate interval (such as 4 to 12 months) to assess effectiveness [19]. A good response is evaluated by [20]:

  • A reduction in severe asthma attacks [20].
  • A reduction or complete elimination of maintenance oral steroid use [20][21].
  • Improved lung function and quality of life [20].

If you are able to reduce long-term oral steroids while on a biologic, your doctor must monitor your adrenal function, as your body may have suppressed its own cortisol production after prolonged pill use [21]. Never taper your steroids without a strict medical plan [22].

Common questions in this guide

How do doctors tell severe asthma from difficult-to-treat asthma?
Difficult-to-treat asthma may be uncontrolled because of missed doses, incorrect inhaler technique, smoking, untreated related conditions, or ongoing workplace triggers. Severe asthma remains uncontrolled even when inhalers are used correctly, related conditions are addressed, and exposures are controlled. Fixing these issues may improve control without a biologic.
Can a biologic make it safe to keep breathing a workplace chemical that triggers my asthma?
No. Biologics target inflammation but do not remove the risk from continued exposure to a sensitizing chemical. Exposure control or removal should remain part of your treatment plan.
How is the right biologic selected for severe environmental asthma?
An asthma specialist reviews blood and breath markers such as IgE, eosinophil count, and FeNO, which is a gas that can indicate airway inflammation. The decision also considers asthma attacks, other conditions, weight, and the eligibility rules for each medicine. This information helps match treatment to the immune pathway involved.
Which biologic medicines may be used for severe asthma?
Options include omalizumab for IgE-driven allergic asthma; mepolizumab, reslizumab, or benralizumab for eosinophil-related inflammation; dupilumab for IL-4 and IL-13 pathways; and tezepelumab for TSLP. The best choice depends on your biomarkers, medical history, and eligibility for the medicine.
What warning signs should I report while taking a biologic?
Redness or swelling at the injection site can occur, and all biologics carry a small risk of a severe allergic reaction. With dupilumab, a rise in eosinophils can rarely be associated with EGPA. Promptly report new numbness or tingling, worsening respiratory symptoms, or a new rash to your clinician.
How will I know if a biologic is working, and how is steroid tapering monitored?
Doctors commonly assess a biologic over about 4 to 12 months by tracking severe attacks, oral steroid use, lung function, and quality of life. If long-term oral steroids are reduced, your clinician may monitor adrenal function because the body may have lowered its own cortisol production. Never change or taper steroid doses without a medical plan.

Get notified when new evidence is published on environmental induced asthma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (22)
  1. 1

    Difficult to Treat and Severe Asthma: Management Strategies.

    Narasimhan K

    American family physician 2021; (103(5)):286-290.

    PMID: 33630543
  2. 2

    Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline.

    Holguin F, Cardet JC, Chung KF, et al.

    The European respiratory journal 2020; (55(1)) doi:10.1183/13993003.00588-2019.

    PMID: 31558662
  3. 3

    Differentiation of adult severe asthma from difficult-to-treat asthma - Outcomes of a systematic assessment protocol.

    von Bülow A, Backer V, Bodtger U, et al.

    Respiratory medicine 2018; (145()):41-47 doi:10.1016/j.rmed.2018.10.020.

    PMID: 30509715
  4. 4

    A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma.

    Sulaiman I, Greene G, MacHale E, et al.

    The European respiratory journal 2018; (51(1)) doi:10.1183/13993003.01126-2017.

    PMID: 29301919
  5. 5

    Remotely Monitored Therapy and Nitric Oxide Suppression Identifies Nonadherence in Severe Asthma.

    Heaney LG, Busby J, Bradding P, et al.

    American journal of respiratory and critical care medicine 2019; (199(4)):454-464 doi:10.1164/rccm.201806-1182OC.

    PMID: 30339770
  6. 6

    Diagnosis and Management of Severe Asthma.

    Chung KF

    Seminars in respiratory and critical care medicine 2018; (39(1)):91-99 doi:10.1055/s-0037-1607391.

    PMID: 29427989
  7. 7

    Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.

    Katsaounou P, Buhl R, Brusselle G, et al.

    Respiratory medicine 2019; (150()):51-62 doi:10.1016/j.rmed.2019.02.003.

    PMID: 30961951
  8. 8

    Biologic Therapies for Severe Asthma: Current Insights and Future Directions.

    Faria N, Costa MI, Fernandes AL, et al.

    Journal of clinical medicine 2025; (14(9)) doi:10.3390/jcm14093153.

    PMID: 40364184
  9. 9

    Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison.

    Menzies-Gow A, Steenkamp J, Singh S, et al.

    Journal of medical economics 2022; (25(1)):679-690 doi:10.1080/13696998.2022.2074195.

    PMID: 35570578
  10. 10

    Efficacy and Safety of Biologics for Oral Corticosteroid-Dependent Asthma: A Systematic Review and Network Meta-Analysis.

    Phinyo P, Krikeerati T, Vichara-Anont I, Thongngarm T

    The journal of allergy and clinical immunology. In practice 2024; (12(2)):409-420 doi:10.1016/j.jaip.2023.11.007.

    PMID: 37972921
  11. 11

    Baseline type 2 biomarker levels and response to tezepelumab in severe asthma.

    Corren J, Pham TH, Garcia Gil E, et al.

    Allergy 2022; (77(6)):1786-1796 doi:10.1111/all.15197.

    PMID: 34913186
  12. 12

    Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study.

    Corren J, Ambrose CS, Griffiths JM, et al.

    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2023; (53(4)):417-428 doi:10.1111/cea.14256.

    PMID: 36507576
  13. 13

    Current and Emerging Biologic Therapies for Severe Asthma.

    Cazzola M, Matera MG, Ora J, et al.

    Drugs 2026; (86(6)):813-840 doi:10.1007/s40265-026-02310-4.

    PMID: 41904357
  14. 14

    Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis.

    Wechsler ME, Klion AD, Paggiaro P, et al.

    The journal of allergy and clinical immunology. In practice 2022; (10(10)):2695-2709 doi:10.1016/j.jaip.2022.05.019.

    PMID: 35636689
  15. 15

    Profiling Blood Hypereosinophilia in Patients on Dupilumab Treatment for Respiratory Conditions: A Real-Life Snapshot.

    Caminati M, Maule M, Bagnasco D, et al.

    The journal of allergy and clinical immunology. In practice 2025; (13(6)):1367-1374.e4 doi:10.1016/j.jaip.2025.01.040.

    PMID: 39956163
  16. 16

    Changes in Peripheral Blood Eosinophil Counts and Risk of Eosinophilic Granulomatosis with Polyangiitis Onset after Initiation of Dupilumab Administration in Adult Patients with Asthma.

    Kushima Y, Shimizu Y, Hoshi H, et al.

    Journal of clinical medicine 2023; (12(17)) doi:10.3390/jcm12175721.

    PMID: 37685789
  17. 17

    Eosinophilic granulomatosis with polyangiitis developed after dupilumab administration in patients with eosinophilic chronic rhinosinusitis and asthma: a case report.

    Suzaki I, Tanaka A, Yanai R, et al.

    BMC pulmonary medicine 2023; (23(1)):130 doi:10.1186/s12890-023-02415-6.

    PMID: 37076824
  18. 18

    Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.

    Rabe KF, Nair P, Brusselle G, et al.

    The New England journal of medicine 2018; (378(26)):2475-2485 doi:10.1056/NEJMoa1804093.

    PMID: 29782224
  19. 19

    [Criteria for evaluation of response to biologics in severe asthma - the Biologics Asthma Response Score (BARS)].

    Milger K, Korn S, Feder C, et al.

    Pneumologie (Stuttgart, Germany) 2023; (77(4)):220-232 doi:10.1055/a-2014-4350.

    PMID: 36796422
  20. 20

    Exploring Definitions and Predictors of Response to Biologics for Severe Asthma.

    Scelo G, Tran TN, Le TT, et al.

    The journal of allergy and clinical immunology. In practice 2024; (12(9)):2347-2361 doi:10.1016/j.jaip.2024.05.016.

    PMID: 38768896
  21. 21

    Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study.

    Menzies-Gow A, Gurnell M, Heaney LG, et al.

    The Lancet. Respiratory medicine 2022; (10(1)):47-58 doi:10.1016/S2213-2600(21)00352-0.

    PMID: 34619104
  22. 22

    Biologic therapies for severe asthma with persistent type 2 inflammation.

    Chandrasekara S, Wark P

    Australian prescriber 2024; (47(2)):36-42 doi:10.18773/austprescr.2024.015.

    PMID: 38737370

This page is for informational purposes only and does not constitute medical advice. Decisions about biologics, workplace exposure, and steroid tapering should be made with your asthma specialist.

Guide contents environmental induced asthma
Research & Literature
04 Modern Standard of Care for Asthma Treatment 06 Managing Your Environment and Workplace Triggers